Using genetics to enable studies on the prevention of Alzheimer's disease - Wikidata - wikimedia - TriplyDB

Using genetics to enable studies on the prevention of Alzheimer's disease

Using genetics to enable studies on the prevention of Alzheimer's disease

http://www.wikidata.org/entity/Q34038890

about

Polyallelic structural variants can provide accurate, highly informative genetic markers focused on diagnosis and therapeutic targets: Accuracy vs. Precision Impaired structural correlates of memory in Alzheimer's disease mice.APOE ε4-TOMM40 '523 haplotypes and the risk of Alzheimer's disease in older Caucasian and African Americans The cis-regulatory effect of an Alzheimer's disease-associated poly-T locus on expression of TOMM40 and apolipoprotein E genes.Community engagement in diverse populations for Alzheimer disease prevention trials.Are APOE ɛ genotype and TOMM40 poly-T repeat length associations with cognitive ageing mediated by brain white matter tract integrity?Insulin resistance in Alzheimer's disease.Effects of low doses of pioglitazone on resting-state functional connectivity in conscious rat brain.The Broad Impact of TOM40 on Neurodegenerative Diseases in Aging Endpoints in preclinical Alzheimer's disease trials.The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations A cytosine-thymine (CT)-rich haplotype in intron 4 of SNCA confers risk for Lewy body pathology in Alzheimer's disease and affects SNCA expression.A Genetics-based Biomarker Risk Algorithm for Predicting Risk of Alzheimer's Disease.CAP--advancing the evaluation of preclinical Alzheimer disease treatments.The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives.Alzheimer's disease susceptibility genes APOE and TOMM40, and brain white matter integrity in the Lothian Birth Cohort 1936.TOMM40'523 variant and cognitive decline in older persons with APOE ε3/3 genotype.The Biological Foundation of the Genetic Association of TOMM40 with Late-onset Alzheimer's disease.Structural variants can be more informative for disease diagnostics, prognostics and translation than current SNP mapping and exon sequencing.New Genetic Approaches to AD: Lessons from APOE-TOMM40 Phylogenetics.Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics.How can we really improve screening methods for AD prevention trials?Characterization of APOE and TOMM40 allele frequencies in the Japanese population.Proteomic differences in brain vessels of Alzheimer's disease mice: Normalization by PPARγ agonist pioglitazone.The TOMM40 poly-T rs10524523 variant is associated with cognitive performance among non-demented elderly with type 2 diabetes.Towards precision medicine in Alzheimer's disease: deciphering genetic data to establish informative biomarkers.Focusing on drug versus disease mechanisms and on clinical subgrouping to advance personalised medicine in psychiatry.Neuropathologic features of TOMM40 '523 variant on late-life cognitive decline.The effects of the TOMM40 poly-T alleles on Alzheimer's disease phenotypes.Biothiols and oxidative stress markers and polymorphisms of and genes in Alzheimer's disease patients

P2860

Q26777805-0B8CC0FE-D2A3-4F4B-B4AA-A63FA1D02986 Q30701096-F0B6C53E-2E39-4DF6-B8DA-C59519E591C4 Q33866039-DDB37B9F-E213-4496-8036-98184A22921D Q33901364-73ABACF4-B001-4A82-85BB-5E3FE1D03268 Q34071045-D0FBD627-6E5A-402B-ADA5-33C59DDA1DB7 Q34370525-E49179BF-9846-49FC-A98F-8C69B3897E30 Q34622157-521C847A-815F-41EF-B0A9-C0819F6B8DD3 Q35073600-43A47D3E-14B0-460B-B6CC-3146D5E1EB58 Q35137172-257A007C-A9A4-4957-AF10-06F4FE5BBF95 Q35694848-F8915562-5706-419F-940E-9C70220BF0C4 Q36165011-2AD7E05B-9A2F-4848-A963-60F7A2BC179F Q36240398-206A4946-3B76-4298-8F05-2967B58F448F Q36754847-07A9E76D-8DB7-4BB5-BE12-8CC5807ED597 Q36843004-242F26C6-BA02-4636-84CA-72E382798E9D Q37656554-BB7F66CA-182F-4F40-BBC4-CD8B9CAEDEFC Q37671476-7E0FBB1B-8ED1-433B-B34C-B554F9EA518D Q38382097-E66D8BE2-7519-4B69-9E01-6C8043DA69B7 Q38646489-D30DF964-7179-407D-8483-D5D9426609A9 Q38685892-5B3DDA4F-BFD8-44EA-A94C-FC6E66F11035 Q38796814-0131958D-6784-491B-BC6B-C26DE8CD3BAC Q38983318-0A7A9F67-A0AB-4B5D-9E25-6103C4D34FDB Q42689730-EB426D54-7845-492C-AD03-F758E677D414 Q43273021-98C23A38-6E24-4932-9729-C5C62FA5D91C Q46528028-A7C8DFF4-8A71-40EC-85ED-1820F7B01A53 Q47159488-80CFD5A8-412E-4BE3-9058-54DD40D9C2F9 Q47929398-D7D995F5-1451-4273-AC6A-FE5D3C9396AB Q48162906-69DAFB8B-1FDE-4048-ADCF-DD063225E028 Q51344905-C2CCF389-1ED7-43B0-9D05-D45D7EBEADE2 Q53396315-FF5EBBBC-CA3E-4CE8-8FBE-89FBFD88498F Q59137800-03A40C92-DD48-4B4B-A1F8-72CF22D7CBE3

P2860

Using genetics to enable studies on the prevention of Alzheimer's disease

http://www.wikidata.org/entity/Q34038890

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Using genetics to enable studies on the prevention of Alzheimer's disease

@ast

Using genetics to enable studies on the prevention of Alzheimer's disease

@en

Using genetics to enable studies on the prevention of Alzheimer's disease

@nl

type

label

Using genetics to enable studies on the prevention of Alzheimer's disease

@ast

Using genetics to enable studies on the prevention of Alzheimer's disease

@en

Using genetics to enable studies on the prevention of Alzheimer's disease

@nl

prefLabel

Using genetics to enable studies on the prevention of Alzheimer's disease

@ast

Using genetics to enable studies on the prevention of Alzheimer's disease

@en

Using genetics to enable studies on the prevention of Alzheimer's disease

@nl

P1433

Q34038890-9DCF5799-8361-42B3-8DCD-C222F6D57A7C

P1476

Q34038890-23105850-CECF-4F7F-8ED4-79008585C80C

P2093

Q34038890-2F22F14D-0543-4ACE-AFBC-DEB2A03D05BB

Q34038890-52B7656B-0FE2-4263-A676-66A39AC80383

Q34038890-5C69BD78-CAE4-43AA-8363-C126E6AD0E7B

Q34038890-85EB930C-C6A9-4C08-B3B1-9968125ED579

Q34038890-8909D0AB-0006-419B-98F9-E5A33AAD2496

Q34038890-C73F8AB0-9E5E-4B06-AF87-BC152F05CEE1

Q34038890-EF366CA1-2A61-4A2E-BB92-E22F6BE5C21C

Q34038890-F5C475FF-BC47-4E6B-8159-F52E6F4C45C5

P2860

Q34038890-0AB0DB9F-99D0-4694-9B26-87D3E018D225

Q34038890-0C4B564C-E18C-4EB1-8AF8-523DFB85B1CF

Q34038890-14CDC606-F8CE-4889-B7AE-1BA9E64C7CEC

Q34038890-1651D552-8E33-4C12-A6C6-B138B9AE3351

Q34038890-170E42CD-4E8B-4709-BDBB-27321AB78C15

Q34038890-185C54C3-7026-4C66-891A-C305ADEABF69

Q34038890-1CDBFC1A-42AF-4A2F-8233-00EB3265B520

Q34038890-1D557641-56BA-47F9-B84C-85E29B46626A

Q34038890-1E5CE164-1330-47B1-A11D-DCEE16245488

Q34038890-23A5ECB0-C316-4F75-B223-8B918AC0FC9E

P304

Q34038890-77C41D33-7378-4146-8EF2-0C90C9BAE851

P31

Q34038890-580E48D0-287E-4E48-8EC4-1ADDD00B8FC8

P356

Q34038890-80085D69-2464-4B7F-ABF4-538FB2A42E11

P407

Q34038890-1DA7A84C-AD17-421C-865C-E66DBA954710

P433

Q34038890-DFEACE0B-2842-4F1D-8B68-9D5E4043DFCC

P478

Q34038890-06ECB4F7-DFB1-49F2-9523-4B4B3E7A3407

P50

Q34038890-AFEF6AD3-EC5F-4FA0-9E4E-E8219867885E

Q34038890-B7A5F57F-D5DB-4663-8BF7-3B3BB7BF83B1

P577

Q34038890-E15C25AB-C6D9-4C28-8EDE-56ED4DCF5C2B

P5875

Q34038890-798F8077-4CC5-4FC0-A63E-9ED32D176D4C

P698

Q34038890-72391078-FA4C-4CB4-A651-FB0D516AD490

P921

Q34038890-AD9D6D0E-8F67-4620-9115-2E984440599B

P932

Q34038890-7E785BEA-0EFC-4CE2-957F-BE3946E665BE

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Using genetics to enable studies on the prevention of Alzheimer's disease

@en

P2093

A D Roses

http://www.w3.org/2001/XMLSchema#string

A M Saunders

http://www.w3.org/2001/XMLSchema#string

D G Crenshaw

http://www.w3.org/2001/XMLSchema#string

D K Burns

http://www.w3.org/2001/XMLSchema#string

I Grossman

http://www.w3.org/2001/XMLSchema#string

K A Welsh-Bohmer

http://www.w3.org/2001/XMLSchema#string

S K Brannan

http://www.w3.org/2001/XMLSchema#string

W K Gottschalk

http://www.w3.org/2001/XMLSchema#string

P2860

Forecasting the global burden of Alzheimer’s disease

APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians

Cholinesterase inhibitors for Alzheimer's disease

Donepezil for dementia due to Alzheimer's disease

Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study

New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs

Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease

Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium

APOE genotype effects on Alzheimer's disease onset and epidemiology

Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history

P304

177-185

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CLPT.2012.222

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P50

Michael W. Lutz

P577

2012-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233948509

http://www.w3.org/2001/XMLSchema#string

P698

23249780

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

4131283

http://www.w3.org/2001/XMLSchema#string